Join Growin Stock Community!
Beta
Back to LLY.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • Revenue by Segments
  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
cash-flow-chart

LLY Cash Flow

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

In Q1'26, Eli Lilly's (LLY) operating cash flow reached $5.33B USD, marking a robust increase from the $3.22B USD reported in Q4'25 and reflecting strong operational performance. Free cash flow for the same period stood at $3.01B USD, up significantly from $0.68B USD in Q4'25, indicating improved liquidity after accounting for capital expenditures. Over the period from Q2'23 to Q1'26, operating cash flow exhibited volatility with early fluctuations, including a negative $0.31B USD in Q4'23, but trended strongly upward overall, peaking at $8.84B USD in Q3'25 before stabilizing at elevated levels, driven by apparent revenue growth in the pharmaceutical sector. Free cash flow followed a similar volatile pattern, with negatives in Q2'23 and Q4'23, but showed marked improvement post-Q1'24, culminating in highs of $6.75B USD in Q3'25, underscoring LLY's enhancing ability to generate surplus cash for investments and shareholder returns amid expanding operations.